Event Information:
Dates
From: 3 June, 2024
To: 6 June, 2024
Location
San Diego, California, USA
Related Models
Join TransCure BioServices at BIO-US 2024
TransCure BioServices is excited to announce our attendance at the BIO International Convention (BIO-US), the world’s largest gathering for the biotechnology industry, happening in June 2024. This premier global event attracts the biggest names and the most innovative minds in biotechnology and pharma, offering an unparalleled platform for networking, learning, and advancing the global biotech landscape.
As leaders in preclinical research services, we are thrilled to join thousands of industry professionals to share our cutting-edge humanized mouse models and showcase how they are driving forward advancements in cancer research, inflammatory diseases, HIV vaccine development, and more. The BIO-US convention is renowned for its wide array of sessions covering the most relevant and pressing topics in biotech today, from therapeutic areas and drug development to environmental sustainability and public health.
Our team, including our CEO, Dr. Sébastien Tabruyn, will be available to discuss how TransCure’s innovative solutions can accelerate your research and development projects. Whether you are looking to start new collaborations, explore the latest trends and technologies, or find the next big opportunity in biotech, TransCure BioServices at BIO-US is where you need to be.
We invite you to meet us there to discover how our expertise and services can benefit your research endeavors.
Mark your calendars for an enriching experience at BIO-US in June 2024. Let’s shape the future of biotechnology together!
For more details on BIO-US and to register, visit convention.bio.org.
Attending in person for TransCure BioServices:
Sebastien Tabruyn, PhD, General Director
Sebastien Tabruyn holds a PhD in Molecular Biology from the University of Liege (Belgium). With over 20 years of experience as a Project Leader in worldwide academic research institutes, including UCSF (California, USA), the Centre for Cancer Biology (Adelaide, Australia), and the University of Maastricht (Netherlands), Sebastien joined TransCure bioServices in 2013 to develop the first immune-oncology humanized mouse models. Before taking on the role of CEO, Sebastien served as the company’s Chief Scientific Officer for six years, where he was instrumental in driving scientific excellence and innovation. Sebastien Tabruyn has published more than 35 peer-reviewed publications, primarily focusing on oncology, inflammation, immunity, and angiogenesis. As CEO, Sebastien commits his leadership and vision to the expansion of TransCure bioServices through the successful delivery of its client needs.